ClinicalTrials.gg
Active, not recruitingNCT05397639Updated Sep 15, 2026

Masupirdine for the Treatment of Agitation in Dementia of the Alzheimer's Type

A Phase 3 interventional study of Masupirdine 50 mg and Masupirdine 100 mg in Agitation and Alzheimer's Type Dementia, sponsored by Suven Life Sciences Limited. Active, not recruiting at 44 sites in 4 countries. Open to participants aged 50 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-09-15.

Primary conditionPsychomotor Agitation(the registry's first term)UnverifiedIs this wrong?The registry often attaches Psychomotor Agitation to studies about something else, and this study's title and listed conditions do not name it. No better condition is named, so the registry's term is kept.

Sponsored by Suven Life Sciences Limited · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
375
Allocation
Randomized
Ages
50 Years to 90 Years
Sex
All
01

Study summary

This study will be conducted to evaluate the efficacy, safety, tolerability, and pharmacokinetics of masupirdine compared to placebo for the treatment of agitation in participants with dementia of the Alzheimer's type.

Read the detailed description

This is a multicenter, randomized, double-blind, placebo-controlled study, consisting of 12 weeks of treatment.

Approximately 375 participants will be enrolled at approximately 50 centers worldwide.

Study medication will be administered orally once-daily from Day 1 through Day 85. Screening will occur within approximately 4 weeks prior to randomization. Following screening procedures for assessment of inclusion and exclusion criteria, eligible participants will be randomized into the study.

02

Conditions studied

  • Agitation
  • Alzheimer's Type Dementia

Browse trials for

Keywords

  • Masupirdine
  • SUVN-502
  • Phase 3
  • Agitation
03

In context

Psychomotor Agitation Unverified

231 studies on the registry are indexed under Psychomotor Agitation; 28 are open to participants now.

This study's planned enrollment of 375 is above the median of 100 across 188 interventional studies indexed under Psychomotor Agitation.

Browse Psychomotor Agitation studies →

Lead sponsor

Suven Life Sciences Limited is the lead sponsor of 15 studies on the registry; 1 is open to participants now.

Of its 7 completed or terminated interventional studies of FDA-regulated products, 2 (29%) have results posted.

Compared within Psychomotor Agitation, the registry's first condition term, which may not be this study's main condition. Counted across the registry records on this site, refreshed daily. How we classify →

04

Who can participate

Ages eligible
50 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has a diagnosis of dementia of the Alzheimer's type according to the National Institute on Aging-Alzheimer's Association (NIA-AA) criteria.
  • Has confirmed agitation using the IPA Consensus Provisional Definition of Agitation in Cognitive Disorders.
  • Has a score between 8 and 24 (both inclusive) on (MMSE).

Exclusion criteria

Exclusion Criteria:

  • Participants with dementia predominantly of the non-Alzheimer's type (e.g., vascular dementia, parkinson's disease, lewy body disease, frontotemporal dementia)
  • Has symptoms of agitation that are not secondary to Alzheimer's disease (eg, pain, other psychiatric disorder, or delirium due to a metabolic disorder, systemic infection, or substance-induced).
  • Participant (or caregiver) is deemed otherwise ineligible for participation in this study in the investigator's judgement.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
375 participants (estimated)

Study arms

  • Experimental
    Low Dose Masupirdine Arm

    Tablet

    Drug: Masupirdine 50 mg

  • Experimental
    High Dose Masupirdine Arm

    Tablet

    Drug: Masupirdine 100 mg

  • Placebo comparator
    Placebo

    Tablet

    Drug: Placebo

Interventions

  • DrugMasupirdine 50 mg

    Tablet, Once Daily

    Also known as: SUVN-502

  • DrugMasupirdine 100 mg

    Tablet, Once Daily

    Also known as: SUVN-502

  • DrugPlacebo

    Matching Placebo Tablet, Once Daily

06

What researchers measure

Primary outcomes

  1. Cohen-Mansfield Agitation Inventory (CMAI)

    Change in CMAI items score aligning to the International Psychogeriatric Association (IPA) agitation criteria domains (physical aggression, excessive motor activity, and verbal aggression). CMAI is a validated 29-item questionnaire to assess agitation. Each item is rated on a 7-point scale ranging from 1 "Never" to 7 "Several times per hour". Higher scores indicate worsening agitation.

    Time frame: From Baseline to Week 12 visit

Secondary outcomes

  1. Modified Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change (mADCS-CGI-C)

    Change in mADCS-CGI-C. The mADCS-CGI-C is a modification of the ADCS-CGI-C instrument that focuses specifically on agitation. It is a 7-point Likert scale that ranges from marked improvement scored as 1 to marked worsening scored as 7. The range is from 1 to 7. Higher scores indicate worsening agitation.

    Time frame: From Baseline to Week 12 visit

07

Study locations

44 sites
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2022 (actual). Primary completion is estimated for Dec 2026, 49 months after the start.

Of 23 phase 3 interventional studies under Psychomotor Agitation, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 47. This study's planned 49 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
May 25, 2022
First posted
May 31, 2022
StartActual
Nov 1, 2022
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Sep 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05397639
Lead sponsor
Suven Life Sciences Limited
Responsible party
Sponsor
First posted
May 31, 2022
Start date
Nov 1, 2022
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Sep 15, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion